Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
JCO Precis Oncol. 2020 Nov;4:882-897. doi: 10.1200/PO.19.00388.
JCO Precis Oncol. 2020.
PMID: 35050761
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.
Attard G, et al.
Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23.
Lancet. 2022.
PMID: 34953525
Free PMC article.
Item in Clipboard
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Schiavone F, Bathia R, Letchemanan K, Masters L, Amos C, Bara A, Brown L, Gilson C, Pugh C, Atako N, Hudson F, Parmar M, Langley R, Kaplan RS, Parker C, Attard G, Clarke NW, Gillessen S, James ND, Maughan T, Sydes MR; past and present members of the STAMPEDE and FOCUS4 Trial Management Group.
Schiavone F, et al.
Trials. 2019 May 29;20(1):264. doi: 10.1186/s13063-019-3216-8.
Trials. 2019.
PMID: 31138317
Free PMC article.
Item in Clipboard
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
Kunisaki KM, Niewoehner DE, Collins G, Aagaard B, Atako NB, Bakowska E, Clarke A, Corbelli GM, Ekong E, Emery S, Finley EB, Florence E, Infante RM, Kityo CM, Madero JS, Nixon DE, Tedaldi E, Vestbo J, Wood R, Connett JE; INSIGHT START Pulmonary Substudy Group.
Kunisaki KM, et al. Among authors: atako nb.
Lancet Respir Med. 2016 Dec;4(12):980-989. doi: 10.1016/S2213-2600(16)30319-8. Epub 2016 Oct 20.
Lancet Respir Med. 2016.
PMID: 27773665
Free PMC article.
Clinical Trial.
Item in Clipboard
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.
Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, Bern H, O'Hara J, McFarlane LR, Lemm NM, McKay PF, Rampling T, Yim YTN, Milinkovic A, Kingsley C, Cole T, Fagerbrink S, Aban M, Tanaka M, Mehdipour S, Robbins A, Budd W, Faust SN, Hassanin H, Cosgrove CA, Winston A, Fidler S, Dunn DT, McCormack S, Shattock RJ; COVAC1 study Group.
Pollock KM, et al.
EClinicalMedicine. 2022 Feb;44:101262. doi: 10.1016/j.eclinm.2021.101262. Epub 2022 Jan 14.
EClinicalMedicine. 2022.
PMID: 35043093
Free PMC article.
Item in Clipboard
Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV.
MacDonald DM, Samorodnitsky S, Wendt CH, Baker JV, Collins G, Kruk M, Lock EF, Paredes R, Poongulali S, Weise DO, Winston A, Wood R, Kunisaki KM; INSIGHT START Pulmonary Substudy Group.
MacDonald DM, et al.
Sci Rep. 2023 Mar 23;13(1):4749. doi: 10.1038/s41598-023-29739-x.
Sci Rep. 2023.
PMID: 36959289
Free PMC article.
Item in Clipboard
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.
Parry MA, Grist E, Mendes L, Dutey-Magni P, Sachdeva A, Brawley C, Murphy L, Proudfoot J, Lall S, Liu Y, Friedrich S, Ismail M, Hoyle A, Ali A, Haran A, Wingate A, Zakka L, Wetterskog D, Amos CL, Atako NB, Wang V, Rush HL, Jones RJ, Leung H, Cross WR, Gillessen S, Parker CC, Chowdhury S; STAMPEDE collaborators; Lotan T, Marafioti T, Urbanucci A, Schaeffer EM, Spratt DE, Waugh D, Powles T, Berney DM, Sydes MR, Parmar MKB, Hamid AA, Feng FY, Sweeney CJ, Davicioni E, Clarke NW, James ND, Brown LC, Attard G.
Parry MA, et al. Among authors: atako nb.
Res Sq [Preprint]. 2023 Feb 8:rs.3.rs-2488586. doi: 10.21203/rs.3.rs-2488586/v1.
Res Sq. 2023.
PMID: 36798177
Free PMC article.
Preprint.
Item in Clipboard
Cite
Cite